Literature DB >> 1131822

The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.

M Edelstein, T Vietti, F Valeriote.   

Abstract

Although both 1-beta-D-arabinofuranosylcytosine (ara-C) and methotrexate are presumed to be toxic as a result of their interference with DNA synthesis, results obtained with L1210 cells in vivo suggest that the combination of ara-C and methotrexate is capable of killing cells by a mechanism not related simply to DNA synthesis inhibition. Simultaneous administration of ara-C and methotrexate, or administration of these two agents within a 10-hr interval, independent of order, produces a synergistic cell kill of L1210 cells but a less than additive effect on normal hematopoietic stem cells. The extent of synergy seems dependent upon the dose of ara-C.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1131822

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML).

Authors:  M Aglietta; P Sonneveld
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.

Authors:  E Cadman; F Eiferman
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

3.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

4.  Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation.

Authors:  T C Stephens; J H Peacock; G G Steel
Journal:  Br J Cancer       Date:  1977-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.